Clinical Trial of BI 425809 Effect on Cognition and Functional Capacity in Schizophrenia - Trial PHRR220921-004972
Access comprehensive clinical trial information for PHRR220921-004972 through Pure Global AI's free database. This Phase 3 trial is sponsored by Boehringer Ingelheim (Philippines), Inc. and is currently Suspended. The study focuses on Schizophrenia.
This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to Philippine Health Research Registry data, helping medical device and pharmaceutical companies navigate clinical research efficiently.
Free Database
Powered by Pure Global AI
840K+ Trials
PHRR220921-004972
Phase 3
Suspended
Trial Details
Philippine Health Research Registry • PHRR220921-004972
Clinical Trial of BI 425809 Effect on Cognition and Functional Capacity in Schizophrenia
A phase III randomized, double-blind, placebo-controlled parallel group trial to examine the efficacy and safety of BI 425809 once daily over 26 week treatment period in patients with schizophrenia (CONNEX-1)
Study Focus
Interventional
Sponsor & Location
Boehringer Ingelheim (Philippines), Inc.
Boehringer Ingelheim Korea Ltd
Australia Brazil Canada China Colombia Germany Greece Italy Japan Mexico New Zealand Norway Philippi
Timeline & Enrollment
Phase 3
Dec 06, 2022
N/A
ICD-10 Classifications
Schizophrenia
Simple schizophrenia
Schizophrenia, unspecified
Other schizophrenia
Paranoid schizophrenia
Data Source
Philippine Health Research Registry
PHRR220921-004972
Non-Device Trial